SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is trending due to recent listings on major trading platforms and active community interest in its focus on bringing the reinsurance market onchain. Investors are closely monitoring its price action and low circulating supply, with many debating the long-term potential of its real-world asset infrastructure.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending due to significant institutional accumulation and speculative buyout activity, as investors anticipate major clinical updates following the company's strong revenue growth in cell therapy. The community is actively debating the potential for an acquisition by J&J or another pharmaceutical suitor, fueled by recent heavy call options volume and the belief that the stock is currently undervalued relative to its CAR-T pipeline potential.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is experiencing renewed market attention as traders monitor potential breakouts above key resistance levels, with the community actively debating whether it is a resilient, undervalued alternative to Bitcoin or a stagnant project. Bullish participants are optimistic about network upgrades and increased transactional volume, while bears express skepticism about its long-term viability and price performance compared to the broader crypto market.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate its potential for a major reversal, fueled by active community engagement, its role as a peer-to-peer payments network, and upcoming technical milestones. While some participants express frustration over recent price consolidation, others are aggressively accumulating based on long-term supply dynamics and the asset's history of stability.

Genius Sports Ltd. engages in the provision of scalable, technology-led products and services to the sports, sports betting, and sports media industries. It also involves in Sports League, which offers technology infrastructure for the collection, integration, and distribution of live data; Sportsbooks, which includes collection of live sports data, odds making, risk management and player marketing; and Sports Media, which provides a range of online marketing and fan engagement tools. The company was founded by Mark Adrian Locke in 2000 and is headquartered in London, United Kingdom.

Genius Sports Limited

Genius Sports is trending as investors weigh its potential as essential infrastructure for the emerging prediction market sector against concerns over ongoing regulatory scrutiny and increased industry competition. The community is actively discussing the company's long-term growth opportunities in sports data, media, and fan engagement while debating the recent volatility and the potential impact of prediction market developments on the broader sports betting landscape.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is experiencing significant volatility and price swings as community members debate whether the stock is a long-term turnaround play or a heavily manipulated retail momentum trade. Investors are actively tracking the impact of recent SEC subpoena disclosures, ongoing insider selling, and the company's expansion into new-vehicle sales, while sentiment remains deeply polarized between those betting on continued short squeezes and those anticipating a major fundamental correction.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is currently trending as the market closely monitors potential M&A activity, with community members actively discussing its strategic pipeline acquisitions and its aggressive pursuit of oncology assets to counter upcoming patent cliffs for Keytruda. Investors are specifically focused on the company's interest in emerging biotech partnerships and clinical trial outcomes, viewing it as a primary contender in major upcoming pharmaceutical bidding wars.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors respond to major milestones in domestic heavy rare earth production at the White Mesa Mill and a $725 million conditional government loan, fueling optimism about the company's role in U.S. national security and independence from Chinese supply chains. The community is actively discussing the strategic importance of this federal support, the potential for future defense and EV industry contracts, and the company's dual-exposure to the surging demand for uranium and critical minerals needed to power AI infrastructure.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending as investors monitor a shift toward broader market rotation and potential M&A activity, with the community actively debating the durability of recent clinical data readouts across the sector. Speculation regarding the impact of upcoming data and possible regulatory changes is fueling intense discussion, while traders carefully watch price support levels amidst broader equity market fluctuations.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors monitor regulatory progress for AXPAXLI, with significant community discourse centered on its potential superiority over current standards for wet AMD and ongoing speculation regarding acquisition interest from major industry players. While bullish sentiment focuses on clinical data and institutional backing, some market participants remain cautious, highlighting debates over the path to FDA approval and the competitive landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Accendra Health Announces Early Results of Offers and Consent Solicitations

Accendra Health, Inc. (NYSE: ACH) (the Company) today announced the early results of the previously announced offers to exchange (the Exchange Offers) any and all of the Companys outstanding 4.500% Senior Notes due 2029 (the 2029 Notes) and 6.625% Senior Notes due 2030 (the 2030 Notes and, together...

Are Options Traders Betting on a Big Move in Accendra Health Stock?

Investors need to pay close attention to ACH stock based on the movements in the options market lately. 

Accendra Health Announces Offers and Consent Solicitations

Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that it has commenced an offer to exchange (the Exchange Offers) any and all of the Companys outstanding 4.500% Senior Notes due 2029 (the 2029 Notes) and 6.625% Senior Notes due 2030 (the 2030 Notes and, together with the 2029 Notes...

Accendra Health (ACH) Q1 2026 Earnings Transcript

Accendra Health (ACH) Q1 2026 Earnings Transcript...

Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction

Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive balance sheet optimization...

WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues

Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.


Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call

Accendra Health, Inc. (NYSE: ACH) (the Company) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange. The...

Accendra Health (NYSE:ACH) Stock Rating Upgraded by Zacks Research

Zacks Research raised shares of Accendra Health from a "strong sell" rating to a "hold" rating in a report on Tuesday...

Is the Options Market Predicting a Spike in Accendra Health Stock?

Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.

Accendra Health Reports Fourth Quarter 2025 Financial Results

Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Companys continuing...

Accendra Health, Inc. engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. Its brands include Apria and Byram Healthcare. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.

Accendra Health Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.08	--	--	N/A
Q1 '26	-$0.10	-$0.04	59.31%	BEAT
Q4 '25	$0.22	$0.21	-5.05%	MISSED
Q3 '25	$0.67	$0.25	-62.96%	MISSED
Q2 '25	$0.62	--	--	N/A

ACHAccendra Health Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest ACH News